Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 6/20 | 0.70 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 3/20 | 0.61 |
| ▸ | BCHE | P06276 | 5/20 | 0.56 |
| ▸ | ACHE | P22303 | 5/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.56 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3002620 | 1.00 | MAOB (0.70) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL3002624 | 1.00 | MAOB (0.70) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL2992577 | 1.00 | MAOB (0.70) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL2993327 | 0.99 | MAOB (0.68) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL3002484 | 0.99 | MAOB (0.68) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL25197831 | 0.99 | MAOB (0.68) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL3002486 | 0.99 | MAOB (0.68) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL2993330 | 0.99 | MAOB (0.68) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL3002404 | 0.96 | MAOB (0.71) | MAOBTNFRSF1AABCG2BCHEACHE | |
| SCHEMBL2998126 | 0.96 | MAOB (0.71) | MAOBTNFRSF1AABCG2BCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7787085-B2 | Optical alignment method and liquid crystal display element | JSR CORPORATION (JP) | 2010-08-31 | — | — | US | disclosed |
| US-20080123046-A1 | OPTICAL ALIGNMENT METHOD AND LIQUID CRYSTAL DISPLAY ELEMENT | JSR CORPORATION (JP) | 2008-05-29 | — | — | US | disclosed |
| EP-1336636-B1 | Liquid crystal aligning agent,method of forming a liquid crystal alignment film and liquid crystal display element | JSR CORP (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-20050259203-A1 | Optical alignment method and liquid crystal display element | JSR CORPORATION (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6887534-B2 | Liquid crystal aligning agent, method of forming a liquid crystal alignment film and liquid crystal display element | JSR CORPORATION (JP) | 2005-05-03 | — | — | US | disclosed |
| US-20040009310-A1 | Liquid crystal aligning agent, method of forming a liquid crystal alignment film and liquid crystal display element | JSR CORPORATION (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1353217-A1 | Optical alignment method and liquid crystal display element | JSR Corporation (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1336636-A1 | Liquid crystal aligning agent,method of forming a liquid crystal alignment film and liquid crystal display element | JSR Corporation (JP) | 2003-08-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAOB 1004/4885TNFRSF1A 2669/4885ABCG2 1606/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885TNFRSF1A 3485/4885ABCG2 3622/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAOB 2435/4885TNFRSF1A 3485/4885ABCG2 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.